People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Pharmaceuticals, Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tricida, Inc. | — | Pharmaceuticals | Series C | $103.1M | $2.0B | 2015 |
| Neurogastrx, Inc. | — | Biotechnology | Series C | $80.0M | $1.7B | 2021 |
| Sparrow Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $73.3M | $386.2M | 2020 |
| CranioVation, Inc. | — | Other Health Care | Series B | $56.7M | $174.9M | 2020 |
| Promentis Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $32.1M | $85.0M | 2009 |
| Symbiomix Therapeutics, LLC | — | Pharmaceuticals | Series B | $25.5M | $204.0M | 2013 |
Klaus Veitinger at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Klaus Veitinger on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Thompson | 2 | 16 |
| Thomas Beck | 2 | 7 |
| Robert Jacks | 2 | 2 |
| Jonathan Root | 1 | 16 |
| David Hirsch | 1 | 16 |
| Rishi Gupta | 1 | 12 |
| Ben Auspitz | 1 | 9 |
| Aaron Royston | 1 | 7 |
| Aaron Sandoski | 1 | 7 |
| Niall O'Donnell | 1 | 7 |
| Zach Scheiner | 1 | 6 |
| Robert Stein | 1 | 6 |
| David Bonita | 1 | 6 |
| David Katz | 1 | 6 |
| Juan-Pablo Mas | 1 | 5 |
| Conrad Wang | 1 | 3 |
| Geoffrey Parker | 1 | 3 |
| Gerrit Klaerner | 1 | 3 |
| Sandra Coufal | 1 | 3 |
| DAVID ALLISON | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.